Associations of renin–angiotensin system inhibitor use with brain insulin signaling and neuropathology
Open Access
- 1 July 2024
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 11 (8) , 2112-2122
Abstract
Objective: To examine the associations of renin–angiotensin system (RAS) inhibitor use with postmortem brain insulin signaling and neuropathology.Methods: Among Religious Orders Study participants, 150 deceased and autopsied older individuals (75 with diabetes matched to 75 without by age at death, sex, and education) had measurements of insulin receptor substrate‐1 (IRS‐1) and RAC‐alpha serine/threonine protein kinase (AKT1) collected in the prefrontal cortex using ELISA and immunohistochemistry. Alzheimer's disease (AD), brain infarcts, and cerebral vessel pathology data were assessed by systematic neuropathologic evaluations. RAS inhibitor use was determined based on visual inspection of medication containers during study visits. The associations of RAS inhibitor use with brain insulin signaling measures and neuropathology were examined using adjusted regression analyses.Results: Of the 90 RAS inhibitor users (54 with diabetes), 65 had used only angiotensin‐converting enzyme inhibitors, 11 only angiotensin II receptor blockers, and 14 used both. RAS inhibitor use was associated with lower pT308AKT1/total AKT1, but not with pS307IRS‐1/total IRS‐1 or the density of cells stained positive for pS616 IRS‐1. RAS inhibitor use was not associated with the level of global AD pathology or amyloid beta burden, but it was associated with a lower tau‐neurofibrillary tangle density. Additionally, we found a significant interaction between diabetes and RAS inhibitors on tangle density. Furthermore, AKT1 phosphorylation partially mediated the association of RAS inhibitor use with tau tangle density. Lastly, RAS inhibitor use was associated with more atherosclerosis, but not with other cerebral blood vessel pathologies or cerebral infarcts.Interpretation: Late‐life RAS inhibitor use may be associated with lower brain AKT1 phosphorylation and fewer neurofibrillary tangles.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (R01NS084965)
- National Institute on Aging (P30AG072975, P30AG10161, R01AG15819, RF1AG059621, RF1AG074549)
This publication has 45 references indexed in Scilit:
- Angiotensin-converting enzyme inhibitors and statins therapies-induced changes in omics profiles in humans and transgenic tau miceBiomedicine & Pharmacotherapy, 2023
- mTOR in Alzheimer disease and its earlier stages: Links to oxidative damage in the progression of this dementing disorderFree Radical Biology and Medicine, 2021
- Brain Insulin Signaling, Alzheimer Disease Pathology, and Cognitive FunctionAnnals of Neurology, 2020
- Association of Amyloid and Tau With Cognition in Preclinical Alzheimer DiseaseJAMA Neurology, 2019
- Impact of Angiotensin Receptor Blockers on Alzheimer Disease Neuropathology in a Large Brain Autopsy SeriesArchives of Neurology, 2012
- Antihypertensive drug use and the risk of dementia in patients with diabetes mellitusAlzheimer's & Dementia, 2012
- Impact of Hypertension on StrokeCurrent Atherosclerosis Reports, 2011
- Cerebral amyloid angiopathy pathology and cognitive domains in older personsAnnals of Neurology, 2010
- Hypertension, insulin resistance, and the metabolic syndromeEndocrinology and Metabolism Clinics of North America, 2004
- Diabetes Mellitus and Risk of Alzheimer Disease and Decline in Cognitive FunctionArchives of Neurology, 2004